Renexxion Ireland Ltd
Peter Milner has extensive work experience in the biopharmaceutical industry. Peter started their career as the Co-Founder, CEO, and later President of ARYx Therapeutics from 1997 to 2010. Peter then served as a Co-Founder and Member of the Board of Directors at Optivia Biotechnology from 2007 to 2018. In 2007, they also became a Member of the Board of Directors at California Healthcare Institute, where they worked until 2015. From 2011 to 2017, Peter held various roles, including Executive Chairman at Armetheon, Member of the Board of Directors at SinuSys Corp., and Member of the Board of Directors at Heart Metabolics. Peter served as the Chief Medical Officer at Retrotope Inc. from 2015 and as the CEO at Renexxion from 2016. Peter also worked as a Director at Solstice from 2013 to 2015. In 2017, Peter joined Espero BioPharma as a Director, where they worked until 2019. Overall, Peter Milner has amassed a wealth of experience in leadership, executive, and board positions in the biopharmaceutical industry.
Peter Milner attended the University of Liverpool from 1974 to 1981, where they obtained a BSc (Hons) MB ChB degree in Medicine.
This person is not in any teams
Renexxion Ireland Ltd
Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).